Idiopathic interstitial pneumonia medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 27: Line 27:
: '''[[Desquamative interstitial pneumonia|Desquamative Interstitial Pneumonia]]'''
: '''[[Desquamative interstitial pneumonia|Desquamative Interstitial Pneumonia]]'''
::* good response to smoking cessation but unknown response to corticosteroids
::* good response to smoking cessation but unknown response to corticosteroids
==General outline of chronic fibrosing IIPs==
*Establishment of the diagnosis is the first critical step in management as misdiagnosis can lead to inappropriate initial therapy. The second step is severity stage to guide treatment choices. Finally, a disease management plan is tailored to the disease severity and patient’s preferences. Follow up assessment is needed to refine treatment options with the disease progression. As no therapy has been proven to be efficacious in this disease, management generally includes some combination of supportive care such as supplemental oxygen and pulmonary rehabilitation, consideration for participation in clinical trials, referral for lung transplant evaluation if possible and early detection and management of comorbidities.<ref name="Raghu-2011">{{Cite journal  | last1 = Raghu | first1 = G. | last2 = Collard | first2 = HR. | last3 = Egan | first3 = JJ. | last4 = Martinez | first4 = FJ. | last5 = Behr | first5 = J. | last6 = Brown | first6 = KK. | last7 = Colby | first7 = TV. | last8 = Cordier | first8 = JF. | last9 = Flaherty | first9 = KR. | title = An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. | journal = Am J Respir Crit Care Med | volume = 183 | issue = 6 | pages = 788-824 | month = Mar | year = 2011 | doi = 10.1164/rccm.2009-040GL | PMID = 21471066 }}</ref><ref name="Walter-2006">{{Cite journal  | last1 = Walter | first1 = N. | last2 = Collard | first2 = HR. | last3 = King | first3 = TE. | title = Current perspectives on the treatment of idiopathic pulmonary fibrosis. | journal = Proc Am Thorac Soc | volume = 3 | issue = 4 | pages = 330-8 | month = Jun | year = 2006 | doi = 10.1513/pats.200602-016TK | PMID = 16738197 }}</ref>


==References==
==References==

Revision as of 19:35, 21 November 2013

Idiopathic Interstitial Pneumonia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Idiopathic interstitial pneumonia from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

CT

Endoscopy

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Future or Investigational Therapies

Case Studies

Case #1

Idiopathic interstitial pneumonia medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Idiopathic interstitial pneumonia medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onIdiopathic interstitial pneumonia medical therapy

CDC on Idiopathic interstitial pneumonia medical therapy

Idiopathic interstitial pneumonia medical therapyin the news

on Idiopathic interstitial pneumonia medical therapy

Directions to Hospitals Treating Idiopathic interstitial pneumonia

Risk calculators and risk factors for Idiopathic interstitial pneumonia medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2];

Overview

As IIPs are heterogenous group of unknown interstitial lung disease with different natural history and clinical course, their management should be based on the clinical subtype. Optimal therapy for IPF is controversial as all currently available medications for IPF are severely limited by the lack of clear understanding of the natural history of IPF, the presence of various forms of study designs; heterogeneous patient groups, disputable diagnostic certainty; variable study duration; differences in medication formulation, dosage, route of administration, and duration of treatment; lack of placebo controls; variable intervals between evaluations and differing types of non quantitative assessment criteria. To date, most of treatment strategies have been based on eliminating or suppressing the inflammatory component. As no pharmacological therapy has been proven a clinical efficacy in altering or reversing the inflammatory process of IPF.

Medical Therapy

The following points are a general summary for the responsiveness of each subtype of IIPs

Chronic Fibrosing IIPs

Idiopathic Pulmonary Fibrosis
  • poor response to corticosteroids and cytotoxic drugs
Idiopathic Nonspecific Interstitial Pneumonia
  • good response to corticosteroids

Acute/Subacute IIPs

Cryptogenic Organizing Pneumonia
  • good response to corticosteroids
Acute Interstitial Pneumonia (Hamman-Rich Syndrome)]
  • unknown response to corticosteroids

Smoking-related IIPs

Respiratory Bronchiolitis-Interstitial Lung Disease
  • good response to smoking cessation but unknown response to corticosteroids
Desquamative Interstitial Pneumonia
  • good response to smoking cessation but unknown response to corticosteroids

General outline of chronic fibrosing IIPs

  • Establishment of the diagnosis is the first critical step in management as misdiagnosis can lead to inappropriate initial therapy. The second step is severity stage to guide treatment choices. Finally, a disease management plan is tailored to the disease severity and patient’s preferences. Follow up assessment is needed to refine treatment options with the disease progression. As no therapy has been proven to be efficacious in this disease, management generally includes some combination of supportive care such as supplemental oxygen and pulmonary rehabilitation, consideration for participation in clinical trials, referral for lung transplant evaluation if possible and early detection and management of comorbidities.[1][2]

References

  1. Raghu, G.; Collard, HR.; Egan, JJ.; Martinez, FJ.; Behr, J.; Brown, KK.; Colby, TV.; Cordier, JF.; Flaherty, KR. (2011). "An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management". Am J Respir Crit Care Med. 183 (6): 788–824. doi:10.1164/rccm.2009-040GL. PMID 21471066. Unknown parameter |month= ignored (help)
  2. Walter, N.; Collard, HR.; King, TE. (2006). "Current perspectives on the treatment of idiopathic pulmonary fibrosis". Proc Am Thorac Soc. 3 (4): 330–8. doi:10.1513/pats.200602-016TK. PMID 16738197. Unknown parameter |month= ignored (help)

Template:WH Template:WS